For the quarter ending 2025-09-30, DNLI made $148,128K in revenue. -$126,740K in net income. Net profit margin of -85.56%.
| Income Statement | 2025-09-30 | 2025-06-30 | 2024-12-31 | 2024-09-30 |
|---|---|---|---|---|
| Research and development | 101,950 | 102,696 | 103,402 | 98,238 |
| General and administrative | 35,484 | 32,267 | 27,648 | 24,949 |
| Total operating expenses | 137,434 | 134,963 | 131,049 | 123,187 |
| Gain from divestiture of small molecule programs | 0 | 0 | 4,846 | - |
| Loss from operations | -137,434 | -134,963 | -123,780 | -123,187 |
| Interest and other income, net | 10,532 | 10,844 | 15,537 | 15,995 |
| Loss before income taxes | - | - | -105,676 | - |
| Income tax expense | - | - | 17 | - |
| Net loss | -126,902 | -124,119 | -108,277 | -107,192 |
| Net unrealized gain (loss) on marketable securities, net of tax | 162 | -1,098 | -2,724 | 8,188 |
| Comprehensive loss | -126,740 | -125,217 | -111,001 | -99,004 |
| Net loss per share, basic (usd per share) | -0.74 | -0.72 | -0.675 | -0.63 |
| Net loss per share, diluted (usd per share) | -0.74 | -0.72 | -0.675 | -0.63 |
| Weighted average number of shares outstanding, basic (in shares) | 172,421,492 | 171,449,847 | -86,907,272.5 | 169,456,988 |
| Weighted average number of shares outstanding, diluted (in shares) | 172,421,492 | 171,449,847 | -86,907,272.5 | 169,456,988 |
Denali Therapeutics Inc. (DNLI)
Denali Therapeutics Inc. (DNLI)